# Invenra

> Invenra is a privately held Madison biotechnology company that helps pharmaceutical and biotech teams discover, assemble, screen, express and license complex therapeutic antibodies. Its B-Body bispecific and T-Body trispecific platforms are designed to make multi-target antibodies behave more like conventional IgG molecules in discovery and manufacturing, while its service business turns partner targets or sequences into validated leads and purified material. The clearest proof point arrived in 2025, when Exelixis began a Phase 1 trial of XB628, a bispecific antibody discovered in part through their collaboration.

- **Founded:** 2011
- **Headquarters:** Madison, United States
- **Founders:** Roland Green (Co-Founder, CEO and Chairman), Emile F. Nuwaysir (Co-Founder and former director)
- **Team size:** Approximately 56 employees in the supplied dataset; LinkedIn reports a 51-200 employee range.
- **Products:** B-Body Bispecific Platform, T-Body Trispecific Platform, Rapid Bispecific Discovery, Rapid Monoclonal Antibody Discovery, B-Body Express
- **Notable:** A partnered molecule, XB628, entered a first-in-human Phase 1 oncology study in 2025., The FDA granted rare pediatric disease and orphan drug designations to internal antibody INV724 for neuroblastoma in 2024., Invenra reports B-Body production yields of 6-11 g/L in stable cell-line expression studies and conventional Protein A purification.

## Products & services

- **B-Body Bispecific Platform** — A human IgG-like bispecific scaffold designed for correct chain pairing, conventional purification, high expression yield, stability, solubility and potential subcutaneous formulation.
- **T-Body Trispecific Platform** — A modular trispecific antibody system for combining three binding functions and screening architectures for applications including T-cell engagers and antibody-drug conjugates.
- **Rapid Bispecific Discovery** — A four-month service that screens more than 30 proprietary human phage libraries, runs 90 selection screens in parallel, functionally evaluates more than 250 bispecific combinations and delivers 10 unique B-Body sequences.
- **Rapid Monoclonal Antibody Discovery** — A discovery service using proprietary human phage-display libraries, cross-reactivity and affinity testing, developability assessment and delivery of 15 monoclonal sequences on an advertised two-month timeline.
- **B-Body Express** — A sequence-to-purified-antibody service with QC analysis and 50 mL, 200 mL or 500 mL expression options; the current site advertises delivery in as little as four to eight weeks.
- **Collaborative Development Partnerships** — Custom programs spanning antigen and assay design, antibody discovery, functional screening, optimization, preclinical support and commercial licensing.

## Achievements

- A partnered molecule, XB628, entered a first-in-human Phase 1 oncology study in 2025.
- The FDA granted rare pediatric disease and orphan drug designations to internal antibody INV724 for neuroblastoma in 2024.
- Invenra reports B-Body production yields of 6-11 g/L in stable cell-line expression studies and conventional Protein A purification.
- A Benchling customer study reports discovery timelines reduced from roughly 26 weeks to eight, 100-fold more sequences analyzed and eightfold more project capacity without added headcount.
- Exelixis expanded its collaboration with Invenra multiple times, including a $15 million upfront payment in 2021.
- Twist Bioscience became a co-exclusive service provider of the B-Body platform in 2026.

## Latest updates

- **2026-04** — Launched 52 Views of Cancer, a patient-and-family art initiative whose card decks are intended for scientific and medical conferences.
- **2026-02** — Licensed B-Body to Twist Bioscience under a co-exclusive service-provider agreement.
- **2025-10** — Announced a collaboration with Xcellon Biologics on bispecific and trispecific antibody-drug conjugates.
- **2025-05** — Exelixis initiated the Phase 1 dose-escalation study of XB628 in advanced solid tumors.
- **2025-05** — Launched the T-Body trispecific platform.
- **2025-04** — Launched B-Body Express for rapid expression and purification of partner-provided antibody sequences.

## Links

- Website: https://invenra.com
- LinkedIn: https://www.linkedin.com/company/invenra
- Twitter/X: https://twitter.com/invenra
- Instagram: https://www.instagram.com/invenrainc/

---

Profile page: https://yespress.io/invenra
Published by YesPress — https://yespress.io
Last updated: 2026-08-22